Europe

AstraZeneca tops out new global R&D center and HQ in Cambridge, UK

Wednesday, April 26, 2017

AstraZeneca marks a key milestone in its successful move to Cambridge, U.K., with the “topping out” of its new, state-of-the-art, strategic R&D center and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.

[Read More]

VolitionRX opens new R&D facility in Belgium

Monday, April 24, 2017

VolitionRx opened its new R&D facility. The new building will enable the company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other biotech and pharmaceutical companies.

[Read More]

GlaxoSmithKline, Regeneron partner to generate genetic sequence data

Thursday, March 23, 2017

Regeneron Pharmaceuticals has announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.

[Read More]